Apollo Hospitals Posts Strong Q4, Boosting Analyst Confidence

Key Growth Drivers in Q4 FY26

Apollo Hospitals Enterprise reported robust financial results for the fourth quarter of fiscal year 2026, with consolidated revenues increasing by 18% compared to the previous year. The hospital division led this growth, posting a 16% revenue increase to ₹3,270 crore, supported by a 9.2% rise in average revenue per patient. The pharmacy segment also performed well, with revenues climbing 20% to ₹2,850 crore, thanks to solid offline sales and plans for new store openings. The company's focus on high-margin services, such as Cardio Thoracic and Vascular Surgery (CTVS), which saw a 22% increase in procedures, contributed significantly to improved profitability. Trading volumes for Apollo Hospitals' shares showed moderate activity following the earnings announcement, indicating steady investor interest.

Expansion Plans and Margin Outlook

Looking ahead, analysts anticipate the hospital segment to maintain a 16% compound annual growth rate (CAGR) in revenue through fiscal years 2026-2028. This growth is expected to be fueled by the addition of around 1,400 new hospital beds by FY28, with approximately 900 beds scheduled to become operational in FY27. The pharmacy business is projected to grow at an 18% revenue CAGR, driven by the addition of about 600 stores annually, mid-teen growth in same-store sales, and high-teen growth in online sales. Although new capacity additions might lead to some short-term margin pressure in FY27, Apollo Hospitals is expected to achieve a 100 basis point expansion in group EBITDA margins, reaching 16% by FY28. This improvement is attributed to the ramp-up of new hospitals, a greater contribution from specialized services, and the increasing profitability of its digital pharmacy operations.

Potential Challenges and Competitive Landscape

Despite the positive outlook, Apollo Hospitals faces potential challenges. The considerable investment in adding 1,400 new beds requires careful financial management to avoid straining short-term cash flows and causing margin dilution during the ramp-up phase. The healthcare sector remains competitive, with companies like Fortis Healthcare and Max Healthcare also expanding their services and capacities. The pharmacy segment must continue to innovate and manage operational complexities to maintain its market position against rivals. Analysts have set a target price of ₹9,444 for March 2027, based on a Sum-of-the-Parts valuation, but execution risks and unforeseen cost increases could impact these projections.

Analyst Reaffirmation and Valuation

Analysts have reiterated their 'Long' rating for Apollo Hospitals stock, highlighting the company's strategic growth initiatives and enhanced operational efficiency across its business units. The projected rise in EBITDA margins to 16% by FY28, combined with steady revenue growth in its hospital and pharmacy segments, supports the target price of ₹9,444. The valuation method, which applies different multiples to its hospital and pharmacy businesses, reflects confidence in Apollo Hospitals' ability to leverage its market presence for sustained profitability.